Intrommune Therapeutics is developing an oral mucosal immunotherapy (OMIT) platform that utilizes a toothpaste-based delivery system to introduce allergens safely and conveniently. This approach addresses the challenges of existing food allergy therapies, providing a daily treatment method that simplifies allergen exposure for over 33 million Americans suffering from food allergies.
Funding
$9.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current food allergy therapies are often burdensome and inconvenient, requiring strict adherence to complex protocols. This can make it difficult for the over 33 million Americans with food allergies to manage their condition effectively.
Solution
Intrommune Therapeutics is developing an oral mucosal immunotherapy (OMIT) platform designed to simplify food allergy management. Their approach utilizes a toothpaste-based delivery system to introduce allergens safely and conveniently. By embedding therapeutic agents in a fully functional toothpaste, the OMIT platform aims to provide a disease-modifying treatment with long-term efficacy through a daily treatment method that integrates seamlessly into a patient's routine.
Target Audience
The primary target audience is the over 33 million Americans suffering from food allergies.
Features
- Toothpaste-based delivery system for convenient daily allergen introduction.
- Oral mucosal immunotherapy (OMIT) platform designed for safe and effective allergen exposure.
- Potential for disease-modifying treatment with long-term efficacy.